IFN-γ Directly Controls IL-33 Protein Level through a STAT1- and LMP2-dependent Mechanism

Journal of Biological Chemistry

Volumn 289, Issue 17, 2014, Pages 11829-11843

  Kopach, Pavel ^a   Lockatell, Virginia ^a   Pickering, Edward M ^a,b   Haskell, Ronald E ^c   Anderson, Richard D ^c   Hasday, Jeffrey D ^a,b   Todd, Nevins W ^a,b   Luzina, Irina G ^a,b   Atamas, Sergei P ^a,b  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b BALTIMORE VA MEDICAL CENTER   (United States)

^c ViraQuest Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOCHEMISTRY; BIOLOGY;

CASPASE-1; DOWN-REGULATION; PROTEASOMES; PROTEIN LEVEL;

PROTEINS;

CASPASE 3; CASPASE 8; GAMMA INTERFERON; INTERLEUKIN 1BETA CONVERTING ENZYME; INTERLEUKIN 33; INTERLEUKIN 4; LATENT MEMBRANE PROTEIN 2; SMALL INTERFERING RNA; STAT1 PROTEIN;

ADENOVIRUS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DOWN REGULATION; EMBRYO; ENZYME INHIBITION; FEMALE; FIBROBLAST CULTURE; GENE REPRESSION; GENE SILENCING; GENE TARGETING; IN VIVO STUDY; LUNG; LUNG FIBROBLAST; MOLECULAR MECHANICS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; PROTEIN PURIFICATION; PROTEIN SUBUNIT; UPREGULATION;

CASPASE; CYTOKINES/INTERFERON; IMMUNOLOGY; INFLAMMATION; INTERFERON-Γ; INTERLEUKIN; INTERLEUKIN-33; INTERLEUKIN-4; LMP2; STAT1;

ANIMALS; BRONCHOALVEOLAR LAVAGE FLUID; CYSTEINE ENDOPEPTIDASES; DOWN-REGULATION; FEMALE; INTERFERON-GAMMA; INTERLEUKIN-4; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; NIH 3T3 CELLS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; STAT1 TRANSCRIPTION FACTOR;

EID: 84899419082     PISSN: 00219258     EISSN: 1083351X     Source Type: Journal    
DOI: 10.1074/jbc.M113.534396     Document Type: Article

References (97)

1. Arend, W. P., Palmer, G., and Gabay, C. (2008) IL-1, IL-18, and IL-33 families of cytokines. Immunol. Rev. 223, 20-38
2. Sims, J. E., and Smith, D. E. (2010) The IL-1 family: regulators of immunity. Nat. Rev. Immunol. 10, 89-102
3. Baekkevold, E. S., Roussigné, M., Yamanaka, T., Johansen, F. E., Jahnsen, F. L., Amalric, F., Brandtzaeg, P., Erard, M., Haraldsen, G., and Girard, J. P. (2003) Molecular characterization of NF-HEV, a nuclear factor preferentially expressed in human high endothelial venules. Am. J. Pathol. 163, 69-79
4. Luzina, I. G., Kopach, P., Lockatell, V., Kang, P. H., Nagarsekar, A., Burke, A. P., Hasday, J. D., Todd, N. W., and Atamas, S. P. (2013) Interleukin-33 potentiates bleomycin-induced lung injury. Am. J. Respir. Cell Mol. Biol. 49, 999-1008.
5. Luzina, I. G., Pickering, E. M., Kopach, P., Kang, P. H., Lockatell, V., Todd, N. W., Papadimitriou, J. C., McKenzie, A. N., and Atamas, S. P. (2012) Full-length IL-33 promotes inflammation but not Th2 response in vivo in an ST2-independent fashion. J. Immunol. 189, 403-410.
6. Lloyd, C. M. (2010) IL-33 family members and asthma: bridging innate and adaptive immune responses. Curr. Opin. Immunol. 22, 800-806.
7. Byers, D. E., Alexander-Brett, J., Patel, A. C., Agapov, E., Dang-Vu, G., Jin, X., Wu, K., You, Y., Alevy, Y., Girard, J. P., Stappenbeck, T. S., Patterson, G. A., Pierce, R. A., Brody, S. L., and Holtzman, M. J. (2013) Long-term IL-33-producing epithelial progenitor cells in chronic obstructive lung disease. J. Clin. Invest. 123, 3967-3982.
8. Walzl, G., Matthews, S., Kendall, S., Gutierrez-Ramos, J. C., Coyle, A. J., Openshaw, P. J., and Hussell, T. (2001) Inhibition of T1/ST2 during respiratory syncytial virus infection prevents T helper cell type 2 (Th2)- but not Th1-driven immunopathology. J. Exp. Med. 193, 785-792.
9. Weinberg, E. O., Shimpo, M., De Keulenaer, G. W., MacGillivray, C., Tominaga, S., Solomon, S. D., Rouleau, J. L., and Lee, R. T. (2002) Expression and regulation of ST2, an interleukin-1 receptor family member, in cardiomyocytes and myocardial infarction. Circulation 106, 2961-2966.
10. Shimpo, M., Morrow, D. A., Weinberg, E. O., Sabatine, M. S., Murphy, S. A., Antman, E. M., and Lee, R. T. (2004) Serum levels of the interleukin- 1 receptor family member ST2 predict mortality and clinical outcome in acute myocardial infarction. Circulation 109, 2186-2190.
11. Weinberg, E. O., Shimpo, M., Hurwitz, S., Tominaga, S., Rouleau, J. L., and Lee, R. T. (2003) Identification of serum soluble ST2 receptor as a novel heart failure biomarker. Circulation 107, 721-726.
12. Sanada, S., Hakuno, D., Higgins, L. J., Schreiter, E. R., McKenzie, A. N., and Lee, R. T. (2007) IL-33 and ST2 comprise a critical biomechanically induced and cardioprotective signaling system. J. Clin. Invest. 117, 1538-1549.
13. Miller, A. M., Xu, D., Asquith, D. L., Denby, L., Li, Y., Sattar, N., Baker, A. H., McInnes, I. B., and Liew, F. Y. (2008) IL-33 reduces the development of atherosclerosis. J. Exp. Med. 205, 339-346.
14. Chapuis, J., Hot, D., Hansmannel, F., Kerdraon, O., Ferreira, S., Hubans, C., Maurage, C. A., Huot, L., Bensemain, F., Laumet, G., Ayral, A. M., Fievet, N., Hauw, J. J., DeKosky, S. T., Lemoine, Y., Iwatsubo, T., Wavrant- Devrièze, F., Dartigues, J. F., Tzourio, C., Buée, L., Pasquier, F., Berr, C., Mann, D., Lendon, C., Alpérovitch, A., Kamboh, M. I., Amouyel, P., and Lambert, J. C. (2009) Transcriptomic and genetic studies identify IL-33 as a candidate gene for Alzheimer's disease. Mol. Psychiatry 14, 1004-1016.
15. Xu, D., Jiang, H. R., Kewin, P., Li, Y., Mu, R., Fraser, A. R., Pitman, N., Kurowska-Stolarska, M., McKenzie, A. N., McInnes, I. B., and Liew, F. Y. (2008) IL-33 exacerbates antigen-induced arthritis by activating mast cells. Proc. Natl. Acad. Sci. U.S.A. 105, 10913-10918.
16. Palmer, G., Talabot-Ayer, D., Lamacchia, C., Toy, D., Seemayer, C. A., Viatte, S., Finckh, A., Smith, D. E., and Gabay, C. (2009) Inhibition of interleukin-33 signaling attenuates the severity of experimental arthritis. Arthritis Rheum. 60, 738-749.
17. Hueber, A. J., Alves-Filho, J. C., Asquith, D. L., Michels, C., Millar, N. L., Reilly, J. H., Graham, G. J., Liew, F. Y., Miller, A. M., and McInnes, I. B. (2011) IL-33 induces skin inflammation with mast cell and neutrophil activation. Eur. J. Immunol. 41, 2229-2237.
18. Sponheim, J., Pollheimer, J., Olsen, T., Balogh, J., Hammarström, C., Loos, T., Kasprzycka, M., Sørensen, D. R., Nilsen, H. R., Küchler, A. M., Vatn, M. H., and Haraldsen, G. (2010) Inflammatory bowel disease-associated interleukin-33 is preferentially expressed in ulceration-associated myofibroblasts. Am. J. Pathol. 177, 2804-2815.
19. Seidelin, J. B., Bjerrum, J. T., Coskun, M., Widjaya, B., Vainer, B., and Nielsen, O. H. (2010) IL-33 is up-regulated in colonocytes of ulcerative colitis. Immunol. Lett. 128, 80-85.
20. Yanaba, K., Yoshizaki, A., Asano, Y., Kadono, T., and Sato, S. (2011) Serum IL-33 levels are raised in patients with systemic sclerosis: association with extent of skin sclerosis and severity of pulmonary fibrosis. Clin. Rheumatol. 30, 825-830.
21. McHedlidze, T., Waldner, M., Zopf, S., Walker, J., Rankin, A. L., Schuchmann, M., Voehringer, D., McKenzie, A. N., Neurath, M. F., Pflanz, S., and Wirtz, S. (2013) Interleukin-33-dependent innate lymphoid cells mediate hepatic fibrosis. Immunity 39, 357-371.
22. Liang, Y., Jie, Z., Hou, L., Aguilar-Valenzuela, R., Vu, D., Soong, L., and Sun, J. (2013) IL-33 induces nuocytes and modulates liver injury in viral hepatitis. J. Immunol. 190, 5666-5675.
23. Carriere, V., Roussel, L., Ortega, N., Lacorre, D. A., Americh, L., Aguilar, L., Bouche, G., and Girard, J. P. (2007) IL-33, the IL-1-like cytokine ligand for ST2 receptor, is a chromatin-associated nuclear factor in vivo. Proc. Natl. Acad. Sci. U.S.A. 104, 282-287.
24. Schmitz, J., Owyang, A., Oldham, E., Song, Y., Murphy, E., McClanahan, T. K., Zurawski, G., Moshrefi, M., Qin, J., Li, X., Gorman, D. M., Bazan, J. F., and Kastelein, R. A. (2005) IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and inducesThelper type 2-associated cytokines. Immunity 23, 479-490.
25. Lefrançais, E., Roga, S., Gautier, V., Gonzalez-de-Peredo, A., Monsarrat, B., Girard, J. P., and Cayrol, C. (2012) IL-33 is processed into mature bioactive forms by neutrophil elastase and cathepsin G. Proc. Natl. Acad. Sci. U.S.A. 109, 1673-1678.
26. Chackerian, A. A., Oldham, E. R., Murphy, E. E., Schmitz, J., Pflanz, S., and Kastelein, R. A. (2007) IL-1 receptor accessory protein and ST2 comprise the IL-33 receptor complex. J. Immunol. 179, 2551-2555.
27. Lüthi, A. U., Cullen, S. P., McNeela, E. A., Duriez, P. J., Afonina, I. S., Sheridan, C., Brumatti, G., Taylor, R. C., Kersse, K., Vandenabeele, P., Lavelle, E. C., and Martin, S. J. (2009) Suppression of interleukin-33 bioactivity through proteolysis by apoptotic caspases. Immunity 31, 84-98.
28. Cayrol, C., and Girard, J. P. (2009) The IL-1-like cytokine IL-33 is inactivated after maturation by caspase-1. Proc. Natl. Acad. Sci. U.S.A. 106, 9021-9026.
29. Liew, F. Y. (2012) IL-33: a Janus cytokine. Ann. Rheum. Dis. 71, i101-i104.
30. Polumuri, S. K., Jayakar, G. G., Shirey, K. A., Roberts, Z. J., Perkins, D. J., Pitha, P. M., and Vogel, S. N. (2012) Transcriptional regulation of murine IL-33 by TLR and non-TLR agonists. J. Immunol. 189, 50-60.
31. Ali, S., Mohs, A., Thomas, M., Klare, J., Ross, R., Schmitz, M. L., and Martin, M. U. (2011) The dual function cytokine IL-33 interacts with the transcription factor NF-κB to dampen NF-κB-stimulated gene transcription. J. Immunol. 187, 1609-1616.
32. Seltmann, J., Werfel, T., and Wittmann, M. (2013) Evidence for a regulatory loop between IFN-γ and IL-33 in skin inflammation. Exp. Dermatol. 22, 102-107.
33. Meephansan, J., Tsuda, H., Komine, M., Tominaga, S., and Ohtsuki, M. (2012) Regulation of IL-33 expression by IFN-γ and tumor necrosis factor- α in normal human epidermal keratinocytes. J. Invest. Dermatol. 132, 2593-2600.
34. Komai-Koma, M., Xu, D., Li, Y., McKenzie, A. N., McInnes, I. B., and Liew, F. Y. (2007) IL-33 is a chemoattractant for human Th2 cells. Eur. J. Immunol. 37, 2779-2786.
35. Louten, J., Rankin, A. L., Li, Y., Murphy, E. E., Beaumont, M., Moon, C., Bourne, P., McClanahan, T. K., Pflanz, S., and de Waal Malefyt, R. (2011) Endogenous IL-33 enhances Th2 cytokine production and T-cell responses during allergic airway inflammation. Int. Immunol. 23, 307-315.
36. Löhning, M., Stroehmann, A., Coyle, A. J., Grogan, J. L., Lin, S., Gutierrez- Ramos, J. C., Levinson, D., Radbruch, A., and Kamradt, T. (1998) T1/ST2 is preferentially expressed on murine Th2 cells, independent of interleukin 4, interleukin 5, and interleukin 10, and important for Th2 effector function. Proc. Natl. Acad. Sci. U.S.A. 95, 6930-6935.
37. Nawijn, M. C., Dingjan, G. M., Ferreira, R., Lambrecht, B. N., Karis, A., Grosveld, F., Savelkoul, H., and Hendriks, R. W. (2001) Enforced expression of GATA-3 in transgenic mice inhibits Th1 differentiation and induces the formation of a T1/ST2-expressing Th2-committed T cell compartment in vivo. J. Immunol. 167, 724-732.
38. Meisel, C., Bonhagen, K., Löhning, M., Coyle, A. J., Gutierrez-Ramos, J. C., Radbruch, A., and Kamradt, T. (2001) Regulation and function of T1/ST2 expression on CD4+ T cells: induction of type 2 cytokine production by T1/ST2 cross-linking. J. Immunol. 166, 3143-3150.
39. Coyle, A. J., Lloyd, C., Tian, J., Nguyen, T., Erikkson, C., Wang, L., Ottoson, P., Persson, P., Delaney, T., Lehar, S., Lin, S., Poisson, L., Meisel, C., Kamradt, T., Bjerke, T., Levinson, D., and Gutierrez-Ramos, J. C. (1999) Crucial role of the interleukin 1 receptor family member T1/ST2 in T helper cell type 2-mediated lung mucosal immune responses. J. Exp. Med. 190, 895-902.
40. Townsend, M. J., Fallon, P. G., Matthews, D. J., Jolin, H. E., and McKenzie, A. N. (2000) T1/ST2-deficient mice demonstrate the importance of T1/ ST2 in developing primary T helper cell type 2 responses. J. Exp. Med. 191, 1069-1076.
41. Zhao, W. H., and Hu, Z. Q. (2012) Up-regulation of IL-33 expression in various types of murine cells by IL-3 and IL-4. Cytokine 58, 267-273.
42. Jiang, H. R., Milovanovi, M., Allan, D., Niedbala, W., Besnard, A. G., Fukada, S. Y., Alves-Filho, J. C., Togbe, D., Goodyear, C. S., Linington, C., Xu, D., Lukic, M. L., and Liew, F. Y. (2012) IL-33 attenuates EAE by suppressing IL-17 and IFN-γ production and inducing alternatively activated macrophages. Eur. J. Immunol. 42, 1804-1814.
43. Groβ, P., Doser, K., Falk, W., Obermeier, F., and Hofmann, C. (2012) IL-33 attenuates development and perpetuation of chronic intestinal inflammation. Inflamm. Bowel Dis. 18, 1900-1909.
44. Imai, Y., Yasuda, K., Sakaguchi, Y., Haneda, T., Mizutani, H., Yoshimoto, T., Nakanishi, K., and Yamanishi, K. (2013) Skin-specific expression of IL-33 activates group 2 innate lymphoid cells and elicits atopic dermatitislike inflammation in mice. Proc. Natl. Acad. Sci. U.S.A. 110, 13921-13926.
45. Bourgeois, E., Van, L. P., Samson, M., Diem, S., Barra, A., Roga, S., Gombert, J. M., Schneider, E., Dy, M., Gourdy, P., Girard, J. P., and Herbelin, A. (2009) The pro-Th2 cytokine IL-33 directly interacts with invariant NKT and NK cells to induce IFN-γ production. Eur. J. Immunol. 39, 1046-1055.
46. Smithgall, M. D., Comeau, M. R., Yoon, B. R., Kaufman, D., Armitage, R., and Smith, D. E. (2008) IL-33 amplifies both Th1- and Th2-type responses through its activity on human basophils, allergen-reactive Th2 cells, iNKT and NK cells. Int. Immunol. 20, 1019-1030.
47. Demyanets, S., Kaun, C., Pentz, R., Krychtiuk, K. A., Rauscher, S., Pfaffenberger, S., Zuckermann, A., Aliabadi, A., Gröger, M., Maurer, G., Huber, K., and Wojta, J. (2013) Components of the interleukin-33/ST2 system are differentially expressed and regulated in human cardiac cells and in cells of the cardiac vasculature. J. Mol. Cell. Cardiol. 60, 16-26.
48. van Erp, K., Dach, K., Koch, I., Heesemann, J., and Hoffmann, R. (2006) Role of strain differences on host resistance and the transcriptional response of macrophages to infection with Yersinia enterocolitica. Physiol. Genomics 25, 75-84.
49. Rock, R. B., Hu, S., Deshpande, A., Munir, S., May, B. J., Baker, C. A., Peterson, P. K., and Kapur, V. (2005) Transcriptional response of human microglial cells to interferon-γ. Genes Immun. 6, 712-719.
50. Hu, X., and Ivashkiv, L. B. (2009) Cross-regulation of signaling pathways by interferon-γ: implications for immune responses and autoimmune diseases. Immunity 31, 539-550.
51. Shuai, K., Ziemiecki, A., Wilks, A. F., Harpur, A. G., Sadowski, H. B., Gilman, M. Z., and Darnell, J. E. (1993) Polypeptide signalling to the nucleus through tyrosine phosphorylation of Jak and Stat proteins. Nature 366, 580-583.
52. Hoey, T. (1997) A new player in cell death. Science 278, 1578-1579.
53. Stark, G. R., Kerr, I. M., Williams, B. R., Silverman, R. H., and Schreiber, R. D. (1998) How cells respond to interferons. Annu. Rev. Biochem. 67, 227-264.
54. Dai, C., and Krantz, S. B. (1999) Interferon gamma induces up-regulation and activation of caspases 1, 3, and 8 to produce apoptosis in human erythroid progenitor cells. Blood 93, 3309-3316.
55. Refaeli, Y., Van Parijs, L., Alexander, S. I., and Abbas, A. K. (2002) Interferon γ is required for activation-induced death of T lymphocytes. J. Exp. Med. 196, 999-1005.
56. Rathbun, R. K., Christianson, T. A., Faulkner, G. R., Jones, G., Keeble, W., O'Dwyer, M., and Bagby, G. C. (2000) Interferon-γ-induced apoptotic responses of Fanconi anemia group C hematopoietic progenitor cells involve caspase 8-dependent activation of caspase 3 family members. Blood 96, 4204-4211.
57. Yang, X., Merchant, M. S., Romero, M. E., Tsokos, M., Wexler, L. H., Kontny, U., Mackall, C. L., and Thiele, C. J. (2003) Induction of caspase 8 by interferon γ renders some neuroblastoma (NB) cells sensitive to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) but reveals that a lack of membrane TR1/TR2 also contributes to TRAIL resistance in NB. Cancer Res. 63, 1122-1129.
58. Ruiz-Ruiz, C., Ruiz de Almodóvar, C., Rodríguez, A., Ortiz-Ferrón, G., Redondo, J. M., and López-Rivas A. (2004) The up-regulation of human caspase-8 by interferon-γ in breast tumor cells requires the induction and action of the transcription factor interferon regulatory factor-1. J. Biol. Chem. 279, 19712-19720.
59. Nicholson, D. W. (1999) Caspase structure, proteolytic substrates, and function during apoptotic cell death. Cell Death Differ. 6, 1028-1042.
60. Thornberry, N. A., and Lazebnik, Y. (1998) Caspases: enemies within. Science 281, 1312-1316.
61. Aki, M., Shimbara, N., Takashina, M., Akiyama, K., Kagawa, S., Tamura, T., Tanahashi, N., Yoshimura, T., Tanaka, K., and Ichihara, A. (1994) Interferon-γ induces different subunit organizations and functional diversity of proteasomes. J. Biochem. 115, 257-269.
62. Gaczynska, M., Goldberg, A. L., Tanaka, K., Hendil, K. B., and Rock, K. L. (1996) Proteasome subunits X and Y alter peptidase activities in opposite ways to the interferon-γ-induced subunits LMP2 and LMP7. J. Biol. Chem. 271, 17275-17280.
63. Groettrup, M., Ruppert, T., Kuehn, L., Seeger, M., Standera, S., Koszinowski, U., and Kloetzel, P. M. (1995) The interferon-γ-inducible 11 S regulator (PA28) and the LMP2/LMP7 subunits govern the peptide production by the 20 S proteasome in vitro. J. Biol. Chem. 270, 23808-23815.
64. Tanaka, K. (1994) Role of proteasomes modified by interferon-γ in antigen processing. J. Leukoc. Biol. 56, 571-575.
65. Tanaka, K., and Kasahara, M. (1998) The MHC class I ligand-generating system: roles of immunoproteasomes and the interferon-γ-inducible proteasome activator PA28. Immunol. Rev. 163, 161-176.
66. Monaco, J. J., and McDevitt, H. O. (1986) The LMP antigens: a stable MHC-controlled multisubunit protein complex. Hum. Immunol. 15, 416-426.
67. Singal, D. P., Ye, M., and Quadri, S. A. (1995) Major histocompatibilityencoded human proteasome LMP2: genomic organization and a new form of mRNA. J. Biol. Chem. 270, 1966-1970.
68. Boes, B., Hengel, H., Ruppert, T., Multhaup, G., Koszinowski, U. H., and Kloetzel, P. M. (1994) Interferon γ stimulation modulates the proteolytic activity and cleavage site preference of 20S mouse proteasomes. J. Exp. Med. 179, 901-909.
69. Goldberg, A. L., Cascio, P., Saric, T., and Rock, K. L. (2002) The importance of the proteasome and subsequent proteolytic steps in the generation of antigenic peptides. Mol. Immunol. 39, 147-164.
70. Ebstein, F., Kloetzel, P. M., Krüger, E., and Seifert, U. (2012) Emerging roles of immunoproteasomes beyond MHC class I antigen processing. Cell. Mol. Life Sci. 69, 2543-2558.
71. Kuhn, D. J., Hunsucker, S. A., Chen, Q., Voorhees, P. M., Orlowski, M., and Orlowski, R. Z. (2009) Targeted inhibition of the immunoproteasome is a potent strategy against models of multiple myeloma that overcomes resistance to conventional drugs and nonspecific proteasome inhibitors. Blood 113, 4667-4676.
72. Díaz-Hernández, M., Hernández, F., Martín-Aparicio, E., Gómez-Ramos, P., Morán, M. A., Castaño, J. G., Ferrer, I., Avila, J., and Lucas, J. J. (2003) Neuronal induction of the immunoproteasome in Huntington's disease. J. Neurosci. 23, 11653-11661.
73. Mishto, M., Bellavista, E., Santoro, A., Stolzing, A., Ligorio, C., Nacmias, B., Spazzafumo, L., Chiappelli, M., Licastro, F., Sorbi, S., Pession, A., Ohm, T., Grune, T., and Franceschi, C. (2006) Immunoproteasome and LMP2 polymorphism in aged and Alzheimer's disease brains. Neurobiol. Aging 27, 54-66.
74. Martin, S., Gee, J. R., Bruce-Keller, A. J., and Keller, J. N. (2004) Loss of an individual proteasome subunit alters motor function but not cognitive function or ambulation in mice. Neurosci. Lett. 357, 76-78.
75. Zu, L., Bedja, D., Fox-Talbot, K., Gabrielson, K. L., Van Kaer, L., Becker, L. C., and Cai, Z. P. (2010) Evidence for a role of immunoproteasomes in regulating cardiac muscle mass in diabetic mice. J. Mol. Cell. Cardiol. 49, 5-15.
76. Cai, Z. P., Shen, Z., Van Kaer, L., and Becker, L. C. (2008) Ischemic preconditioning- induced cardioprotection is lost in mice with immunoproteasome subunit low molecular mass polypeptide-2 deficiency. FASEB J. 22, 4248-4257.
77. Moebius, J., van den Broek, M., Groettrup, M., and Basler, M. (2010) Immunoproteasomes are essential for survival and expansion of T cells in virus-infected mice. Eur. J. Immunol. 40, 3439-3449.
78. Ding, Q., Martin, S., Dimayuga, E., Bruce-Keller, A. J., and Keller, J. N. (2006) LMP2 knock-out mice have reduced proteasome activities and increased levels of oxidatively damaged proteins. Antioxid. Redox Signal. 8, 130-135.
79. Pickering, A. M., Koop, A. L., Teoh, C. Y., Ermak, G., Grune, T., and Davies, K. J. (2010) The immunoproteasome, the 20S proteasome and the PA28αβ proteasome regulator are oxidative-stress-adaptive proteolytic complexes. Biochem. J. 432, 585-594.
80. Atamas, S. P., Luzina, I. G., Dai, H., Wilt, S. G., and White, B. (2002) Synergy between CD40 ligation and IL-4 on fibroblast proliferation involves IL-4 receptor signaling. J. Immunol. 168, 1139-1145.
81. Atamas, S. P., Luzina, I. G., Choi, J., Tsymbalyuk, N., Carbonetti, N. H., Singh, I. S., Trojanowska, M., Jimenez, S. A., and White, B. (2003) Pulmonary and activation-regulated chemokine stimulates collagen production in lung fibroblasts. Am. J. Respir. Cell Mol. Biol. 29, 743-749.
82. Atamas, S. P., Yurovsky, V. V., Wise, R., Wigley, F. M., Goter Robinson, C. J., Henry, P., Alms, W. J., and White, B. (1999) Production of type 2 cytokines by CD8+lung cells is associated with greater decline in pulmonary function in patients with systemic sclerosis. Arthritis Rheum. 42, 1168-1178.
83. Luzina, I. G., and Atamas, S. P. (2012) CCR6 is not necessary for functional effects of human CCL18 in a mouse model. Fibrogenesis Tissue Repair 5, 2.
84. Luzina, I. G., Highsmith, K., Pochetuhen, K., Nacu, N., Rao, J. N., and Atamas, S. P. (2006) PKCα mediates CCL18-stimulated collagen production in pulmonary fibroblasts. Am. J. Respir. Cell Mol. Biol. 35, 298-305.
85. Luzina, I. G., Lockatell, V., Todd, N. W., Highsmith, K., Keegan, A. D., Hasday, J. D., and Atamas, S. P. (2011) Alternatively spliced variants of interleukin-4 promote inflammation differentially. J. Leukoc. Biol. 89, 763-770.
86. Luzina, I. G., Lockatell, V., Todd, N. W., Keegan, A. D., Hasday, J. D., and Atamas, S. P. (2011) Splice isoforms of human interleukin-4 are functionally active in mice in vivo. Immunology 132, 385-393.
87. Luzina, I. G., Papadimitriou, J. C., Anderson, R., Pochetuhen, K., and Atamas, S. P. (2006) Induction of prolonged infiltration of T lymphocytes and transient T lymphocyte-dependent collagen deposition in mouse lungs following adenoviral gene transfer of CCL18. Arthritis Rheum. 54, 2643-2655.
88. Luzina, I. G., Todd, N. W., Nacu, N., Lockatell, V., Choi, J., Hummers, L. K., and Atamas, S. P. (2009) Regulation of pulmonary inflammation and fibrosis through expression of integrins αVβ3 and αVβ5 on pulmonary T lymphocytes. Arthritis Rheum. 60, 1530-1539.
89. Nacu, N., Luzina, I. G., Highsmith, K., Lockatell, V., Pochetuhen, K., Cooper, Z. A., Gillmeister, M. P., Todd, N. W., and Atamas, S. P. (2008) Macrophages produce TGF-β-induced (β-ig-h3) following ingestion of apoptotic cells and regulate MMP14 levels and collagen turnover in fibroblasts. J. Immunol. 180, 5036-5044.
90. Pochetuhen, K., Luzina, I. G., Lockatell, V., Choi, J., Todd, N. W., and Atamas, S. P. (2007) Complex regulation of pulmonary inflammation and fibrosis by CCL18. Am. J. Pathol. 171, 428-437.
91. Anderson, R. D., Haskell, R. E., Xia, H., Roessler, B. J., and Davidson, B. L. (2000) A simple method for the rapid generation of recombinant adenovirus vectors. Gene Ther. 7, 1034-1038.
92. Starcher, B., and Williams, I. (1989)Amethod for intratracheal instillation of endotoxin into the lungs of mice. Lab. Anim. 23, 234-240.
93. Driscoll, K. E., Costa, D. L., Hatch, G., Henderson, R., Oberdorster, G., Salem, H., and Schlesinger, R. B. (2000) Intratracheal instillation as an exposure technique for the evaluation of respiratory tract toxicity: uses and limitations. Toxicol. Sci. 55, 24-35.
94. Yin, H., Li, X. Y., Jin, X. B., Zhang, B. B., Gong, Q., Yang, H., Zheng, F., Gong, F. L., and Zhu, J. Y. (2010) IL-33 prolongs murine cardiac allograft survival through induction of TH2-type immune deviation. Transplantation 89, 1189-1197.
95. Liew, F. Y., Pitman, N. I., and McInnes, I. B. (2010) Disease-associated functions of IL-33: the new kid in the IL-1 family. Nat. Rev. Immunol. 10, 103-110.
96. Ando, M., Takahashi, Y., Nishikawa, M., Watanabe, Y., and Takakura, Y. (2012) Constant and steady transgene expression of interferon-γ by optimization of plasmid construct for safe and effective interferon-γ gene therapy. J. Gene Med. 14, 288-295.
97. Badea, I., Virtanen, C., Verrall, R. E., Rosenberg, A., and Foldvari, M. (2012) Effect of topical interferon-γ gene therapy using gemini nanoparticles on pathophysiological markers of cutaneous scleroderma in Tsk/γ mice. Gene Ther. 19, 978-987